Johnson & Johnson has announced the submission of a Marketing Authorisation Application $(MAA)$ to the European Medicines Agency $(EMA)$ for the approval of nipocalimab, marketed as IMAAVY™, for the treatment of generalized myasthenia gravis (gMG). This submission, made in September 2024, seeks to expand the use of IMAAVY, an FcRn blocker, which has already received U.S. FDA approval for a broad range of gMG patients, including those with anti-AChR and anti-MuSK antibodies, aged 12 and older. The application is part of Johnson & Johnson's efforts to provide consistent and sustained disease control for individuals living with this chronic autoantibody disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.